PXT3003 Continues to Safely Treat CMT1A Patients Over Long Term
Pharnext’s PXT3003, a potential treatment for Charcot–Marie–Tooth type 1A (CMT1A), continues to show sustained safety and efficacy in a Phase 3 open-label extension study. Data collected in April show that PXT3003 continues to ease disabilities, based on scores in the overall neuropathy limitations scale (ONLS), a…